ITCMDBv1
Clinical TrialID 3745

Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia

NCT01503359

Schizophrenia

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
3745
Evidence Id
3745
Core Evidence Id
3745
Source Clinical Trial Id
3718
Herb2 Clinical Trial Id
HBCT003718
Nct Id
NCT01503359
Title
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia
Status
Completed
Phase
Phase 2
Study Result
No
Study Condition
Schizophrenia
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Intervention
DIETARY_SUPPLEMENT: Sarcosine
Intervention Allocation
Randomized
Intervention Model
Parallel
Intervention Mask
Double
Intervention Purpose
Treatment
Gender
All
Age
Adult
Enrollment
70
Outcome Measure
Assessment of sarcosine vs. placebo impact on schizophrenia symptoms using Positive and Negative Syndrome Scale (PANSS)., Both arms, every visit, 6 months
Sponsor Collaborator
Medical University of Lodz
Funded By
OTHER
Location
Central Clinical Hospital, Łódź, Czechosłowacka 8/10, 92-216, Poland
Other Id
PULSAR|N N402 268836
Start Date
2012-01
Primary Completion Date
2015-02
Completion Date
2016-01
First Posted
2012-01-04
Results First Posted
Last Update Posted
2016-09-16
Study Document
Study Url
https://clinicaltrials.gov/study/NCT01503359
Title Cn
Title En
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia
Bilingual Status
semi_complete